Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antivirals divestiture

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham to sell worldwide rights for the Rx antivirals Vectavir/Denavir (penciclovir) and Famvir (famciclovir) to Novartis for $1.63 bil. The deal is contingent upon FTC approval of the Glaxo SmithKline merger. Novartis will market the products with the antifungal Lamisil and its hormone replacement therapies. FDA rejected SB's attempted Rx-to-OTC switch of Denavir in 1999 and said in a March guidance it disfavors the use of such antiviral drugs in an OTC setting (1"The Tan Sheet" March 13, p. 3)

You may also be interested in...



OTC Antiviral Agents For Herpes Cold Sores Disfavored By FDA

The future of potential OTC antiviral treatments for herpes labialis, including Avanir Pharmaceuticals' docosanol 10% cream, is questionable in light of FDA's announcement that it disfavors use of such antiviral drugs in a nonprescription setting.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel